National Bank of Canada FI Acquires 308 Shares of Qiagen (NYSE:QGEN)

National Bank of Canada FI increased its position in Qiagen (NYSE:QGEN) by 1.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 25,636 shares of the company’s stock after buying an additional 308 shares during the period. National Bank of Canada FI’s holdings in Qiagen were worth $1,155,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Massmutual Trust Co. FSB ADV raised its position in Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after purchasing an additional 243 shares during the period. CWM LLC raised its position in Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after buying an additional 269 shares during the last quarter. Atria Investments Inc boosted its stake in shares of Qiagen by 6.0% in the third quarter. Atria Investments Inc now owns 7,632 shares of the company’s stock worth $348,000 after buying an additional 433 shares during the last quarter. Private Advisor Group LLC grew its position in shares of Qiagen by 8.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,251 shares of the company’s stock valued at $285,000 after acquiring an additional 461 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

QGEN has been the subject of several research reports. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research report on Thursday, October 17th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $54.00 price target (up from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.15.

Qiagen Stock Down 1.2 %

Shares of NYSE:QGEN opened at $45.40 on Friday. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The stock has a market capitalization of $10.36 billion, a P/E ratio of 116.41, a PEG ratio of 3.57 and a beta of 0.35. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The stock has a 50-day simple moving average of $43.21 and a 200-day simple moving average of $43.71.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.